Keros Therapeutics (NASDAQ:KROS – Get Free Report) announced its earnings results on Thursday. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.29), FiscalAI reports. The firm had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.
Keros Therapeutics Price Performance
KROS stock traded down $0.94 on Thursday, reaching $11.05. 536,817 shares of the company traded hands, compared to its average volume of 389,285. The company has a market cap of $218.68 million, a P/E ratio of 5.94 and a beta of 0.95. Keros Therapeutics has a one year low of $10.32 and a one year high of $22.55. The firm has a fifty day simple moving average of $11.55 and a 200-day simple moving average of $15.77.
Analysts Set New Price Targets
Several research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.40.
Institutional Trading of Keros Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of KROS. Tower Research Capital LLC TRC increased its stake in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. New York State Common Retirement Fund increased its stake in Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after purchasing an additional 988 shares in the last quarter. Sherbrooke Park Advisers LLC bought a new stake in Keros Therapeutics during the 3rd quarter valued at about $176,000. Finally, XTX Topco Ltd bought a new stake in shares of Keros Therapeutics in the 4th quarter worth $212,000. 71.56% of the stock is currently owned by institutional investors.
Keros Therapeutics Company Profile
Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.
Read More
- Five stocks we like better than Keros Therapeutics
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
